Exploring Titanium(IV) Complexes as Potential Antimicrobial Compounds

Abstract

Due to the rapid mutation of pathogenic microorganisms, drug-resistant superbugs have evolved. Antimicrobial-resistant germs may share their resistance genes with other germs, making them untreatable. The search for more combative antibiotic compounds has led researchers to explore metal-based strategies centered on perturbing the bioavailability of essential metals in microbes and examining the therapeutic potential of metal complexes. Given the limited knowledge on the application of titanium(IV), in this work, eight Ti(IV) complexes and some of their corresponding ligands were screened by the Community for Open Antimicrobial Drug Discovery for antimicrobial activity. The compounds were selected for evaluation because of their low cytotoxic/antiproliferative behavior against a human non-cancer cell line. At pH 7.4, these compounds vary in terms of their solution stability and ligand exchange lability; therefore, an assessment of their solution behavior provides some insight regarding the importance of the identity of the metal compound to the antimicrobial therapeutic potential. Only one compound, Ti(deferasirox)2, exhibited promising inhibitory activity against the Gram-positive bacteria methicillin-resistant Staphylococcus aureus and minimal toxicity against human cells. The ability of this compound to undergo transmetalation with labile Fe(III) sources and, as a consequence, inhibit Fe bioavailability and ribonucleotide reductase is evaluated as a possible mechanism for its antibiotic effect.

Optically Transparent TiO2 and ZnO Photocatalytic Thin Films via Salicylate-Based Sol Formulations

“…In both instances, the emerging spectral features attributed to the salicylate formation exhibit an increase proportional to that of the precursor concentration. The evidence of bidentate bridging configuration, reliant on both the carboxylic and phenolic moieties of SA for the Ti[SA] complex and exclusively on the carboxyl group for the Zn[SA] one aligns with the existing literature regarding the preferred complexation modes of these ions with catechol molecules [34,58,59]. Drawing from this insight, it is plausible to infer that the Ti[SA] structure aligns with the H 2 Ti[SA] 3 configuration elucidated by Gigant et al [33].…”

Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways

“…Metal complexes constitute a vast pipeline of potential active drugs with great promise for various biomedical applications [14][15][16]. As recent examples, silver N-heterocyclic carbenes with long N-alkyl chains [17], titanium(IV) complexes [18] or platinum cyclooctadiene complexes [19] have been reported for their antibacterial properties. Regarding ruthenium complexes, ruthenium(II) polypyridyl complexes (hereafter abbreviated as [Ru(II)]) are endowed with peculiar properties, making them promising chemotherapeutic candidates [20][21][22].…”

Using Nuclear Magnetic Resonance to Troubleshoot a Stability Issue in a Real-World Formulation Chassis—Application to Consumer Oral Healthcare

“…To validate the characterization of the degradants, DOSY spectra were used to generate an MW vs. LogD calibration curve to determine the approximate MW of the assigned degradant peaks (Figure 4). Combining the observed 1 H signals with the DOSY spectra enabled the identification of the degradants [22][23][24] (Figure 4). To validate the characterization of the degradants, DOSY spectra were used to generate an MW vs. LogD calibration curve to determine the approximate MW of the assigned degradant peaks (Figure 4).…”

“…To validate the characterization of the degradants, DOSY spectra were used to generate an MW vs. LogD calibration curve to determine the approximate MW of the assigned degradant peaks (Figure 4). Combining the observed 1 H signals with the DOSY spectra enabled the identification of the degradants [22][23][24] (Figure 4). A further validation of this observation was achieved through control sample spiking (see Supporting Information Figure S2).…”